20:34 , Apr 27, 2018 |  BC Week In Review  |  Financial News

Mereo postpones NASDAQ listing

Mereo BioPharma Group plc (LSE:MPH) said on April 26 it postponed an offering to list its ADSs on NASDAQ and withdrew a concurrent placing, citing market conditions. According to an April 9 SEC filing, the company...
17:17 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Mereo's BGS-649 meets in Phase IIb for hypogonadism

Mereo BioPharma Group plc (LSE:MPH) reported top-line data from a Phase IIb trial in 271 obese men with hypogonadotropic hypogonadism showing that all three doses of once-weekly oral BGS-649 met the primary endpoint of normalizing...
13:16 , Mar 9, 2017 |  BC Week In Review  |  Clinical News

BGS-649: Ph IIb ongoing

An IDMC recommended continuation of a double-blind, placebo-controlled, international Phase IIb trial evaluating 3 doses of oral BGS-649 once weekly for 24 weeks based on an interim analysis conducted after the first 93 patients completed...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Company News

Novartis, Mereo BioPharma deal

Start-up Mereo acquired three Phase II compounds from Novartis in exchange for an undisclosed equity stake. Novartis is eligible for milestone payments and royalties. BPS-804 is a human mAb for the Orphan bone disease...
07:00 , Aug 3, 2015 |  BioCentury  |  Finance

From Phase4 to Mereo

The leadership team behind Phase4 Ventures is branching out from its traditional venture roots to launch newco Mereo BioPharma Group Ltd., which aims to provide an alternative for pharmas looking to advance mid-stage pipelines in...
01:07 , Jul 30, 2015 |  BC Extra  |  Top Story

Mereo raises $119M, acquires three Novartis programs<span class="*Red-type+bold">

Mereo BioPharma Group Ltd. (London, U.K.) debuted on Wednesday with $119 million (L76.7 million) and three clinical-stage programs acquired from Novartis AG (NYSE:NVS; SIX:NOVN). Woodford Investment Management and Invesco Perpetual invested in Mereo; Novartis also...